Bernd Kasper

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. pmc Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib
    Bernd Kasper
    Sarcoma Unit, ITM Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Biomed Res Int 2013:389672. 2013
  2. doi request reprint Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Onkologie 31:107-12. 2008
  3. doi request reprint Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Oncology 73:58-64. 2007
  4. ncbi request reprint Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma
    Bernd Kasper
    University of Heidelberg, Department of Internal Medicine V, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Rev Recent Clin Trials 2:206-11. 2007
  5. doi request reprint [Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma]
    B Kasper
    Abteilung Innere Medizin V Hämatologie, Onkologie und Rheumatologie, Medizinische Klinik, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg
    Dtsch Med Wochenschr 134:1922-6. 2009
  6. doi request reprint Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study
    B Kasper
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Bone Marrow Transplant 45:1234-8. 2010
  7. ncbi request reprint The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas
    Bernd Kasper
    University of Heidelberg, Mannheim University Medical Center, ITM Interdisciplinary Tumour Center Mannheim, Sarcoma Unit, D 68167 Mannheim, Germany
    Hell J Nucl Med 13:40-4. 2010
  8. doi request reprint Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib
    Bernd Kasper
    Sarcoma Unit, ITM Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Eur J Nucl Med Mol Imaging 37:1876-82. 2010
  9. pmc Desmoid tumors: clinical features and treatment options for advanced disease
    Bernd Kasper
    Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor Kutzer Ufer 1 3, D 68167 Mannheim, Germany
    Oncologist 16:682-93. 2011
  10. ncbi request reprint Dose-intensive chemotherapy with stem cell support as a treatment strategy for bone and soft-tissue sarcomas
    Bernd Kasper
    University of Heidelberg, Department of Internal Medicine V, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Curr Stem Cell Res Ther 1:29-35. 2006

Detail Information

Publications31

  1. pmc Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib
    Bernd Kasper
    Sarcoma Unit, ITM Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Biomed Res Int 2013:389672. 2013
    ..This is the first larger series of desmoid patients monitored using PET showing that early SUV changes may help to discriminate responders from nonresponders and, thus, to decide whether imatinib therapy should be continued...
  2. doi request reprint Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Onkologie 31:107-12. 2008
    ..We used 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with soft tissue sarcoma (STS). Treatment effect was assessed with regard to prediction of therapy outcome...
  3. doi request reprint Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Oncology 73:58-64. 2007
    ..The prognosis of patients with advanced sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients or not is controversial...
  4. ncbi request reprint Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma
    Bernd Kasper
    University of Heidelberg, Department of Internal Medicine V, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Rev Recent Clin Trials 2:206-11. 2007
    ....
  5. doi request reprint [Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma]
    B Kasper
    Abteilung Innere Medizin V Hämatologie, Onkologie und Rheumatologie, Medizinische Klinik, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg
    Dtsch Med Wochenschr 134:1922-6. 2009
    ..We used 2-deoxy-2-[(18)F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with soft tissue sarcoma (STS). Treatment effect was assessed with regard to prediction of therapy outcome...
  6. doi request reprint Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study
    B Kasper
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Bone Marrow Transplant 45:1234-8. 2010
    ..The subgroup of patients treated with high-dose chemotherapy gained significant survival benefit. Nevertheless, high-dose chemotherapy as a possible consolidation strategy remains highly investigational...
  7. ncbi request reprint The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas
    Bernd Kasper
    University of Heidelberg, Mannheim University Medical Center, ITM Interdisciplinary Tumour Center Mannheim, Sarcoma Unit, D 68167 Mannheim, Germany
    Hell J Nucl Med 13:40-4. 2010
    ..In conclusion, PET is emerging as an important imaging modality in the management of patients with soft tissue sarcomas...
  8. doi request reprint Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib
    Bernd Kasper
    Sarcoma Unit, ITM Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Eur J Nucl Med Mol Imaging 37:1876-82. 2010
    ..We used (18)F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec)...
  9. pmc Desmoid tumors: clinical features and treatment options for advanced disease
    Bernd Kasper
    Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor Kutzer Ufer 1 3, D 68167 Mannheim, Germany
    Oncologist 16:682-93. 2011
    ..This review describes treatment options and management strategies for patients with desmoid tumors with a focus on advanced disease...
  10. ncbi request reprint Dose-intensive chemotherapy with stem cell support as a treatment strategy for bone and soft-tissue sarcomas
    Bernd Kasper
    University of Heidelberg, Department of Internal Medicine V, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Curr Stem Cell Res Ther 1:29-35. 2006
    ....
  11. ncbi request reprint Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
    Bernd Kasper
    University of Heidelberg, Department of Internal Medicine V, Heidelberg, Germany
    Curr Opin Oncol 19:336-40. 2007
    ....
  12. ncbi request reprint Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Leuk Lymphoma 48:746-53. 2007
    ..However, the present data show no advantage of combined FDG/FLT studies over FDG alone with respect to the prediction of survival...
  13. ncbi request reprint Novel treatment strategies for malignant melanoma: a new beginning?
    Bernd Kasper
    Clinic of Medical Oncology, Institut Jules Bordet, Boulevard de Waterloo 125, Brussels 1000, Belgium
    Crit Rev Oncol Hematol 62:16-22. 2007
    ....
  14. ncbi request reprint Novel treatment strategies for soft tissue sarcoma
    Bernd Kasper
    Clinic of Medical Oncology, Institut Jules Bordet, boulevard de Waterloo, 125, Brussels 1000, Belgium
    Crit Rev Oncol Hematol 62:9-15. 2007
    ....
  15. ncbi request reprint Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp
    Bernd Kasper
    Clinic of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    Anticancer Drugs 17:1223-5. 2006
    ..Our patient is now in sustained remission with minimal toxicity. We conclude that antitumor activity of metastatic dermatofibrosarcoma protuberans can be obtained with imatinib mesylate treatment with minimal side-effects...
  16. doi request reprint Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis
    Antonia Dimitrakopoulou-Strauss
    Medical PET Group Biological Imaging E0601, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
    Eur J Nucl Med Mol Imaging 37:1481-9. 2010
    ..The goal of the study was to evaluate the impact of full kinetic analysis and assess its value with regard to the therapy outcome based on survival data...
  17. pmc A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma
    Thomas Schmitt
    Department of Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    BMC Cancer 11:510. 2011
    ..Here we report on the results of our non-randomized phase II study on neo-adjuvant treatment for high-risk STS...
  18. doi request reprint Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study
    Antonia Dimitrakopoulou-Strauss
    Medical PET Group Biological Imaging, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
    J Nucl Med 51:551-8. 2010
    ..The goal of the study was to evaluate the impact of early dPET studies and assess their value with regard to the therapy outcome using histopathologic data...
  19. pmc The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Mar Drugs 7:331-40. 2009
    ....
  20. ncbi request reprint Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
    Bernd Kasper
    University of Heidelberg, Department of Internal Medicine V, Heidelberg, Germany
    Oncology 68:115-21. 2005
    ..On the basis of our own data, we would like to emphasize the importance of high-dose chemotherapy in the treatment of sarcomas...
  21. ncbi request reprint Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
    Dig Dis 24:207-11. 2006
    ..Imatinib mesylate (Glivec) is an orally administered competitive inhibitor of tyrosine kinases associated with the KIT, ABL protein, licensed for the treatment of metastatic GIST since 2002 in Germany...
  22. ncbi request reprint A new therapeutic approach in patients with advanced sarcoma
    Bernd Kasper
    University of Heidelberg, Department of Internal Medicine V, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    Int J Clin Oncol 10:438-40. 2005
    ..This new triple combination of low-dose trofosfamide, pioglitazone, and rofecoxib may represent a feasible new alternative in the palliative treatment of sarcoma patients...
  23. doi request reprint New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma
    Thomas Schmitt
    University of Heidelberg, Department of Internal Medicine V, Germany
    Expert Rev Anticancer Ther 9:1159-67. 2009
    ..With further insight into the biology of STS and the combination of new treatment options with modern imaging techniques, we will most certainly be able to improve clinical outcome in patients with STS in the upcoming years...
  24. doi request reprint Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931
    Bernd Kasper
    University of Heidelberg, Mannheim University Medical Center, Mannheim, Germany
    Eur J Cancer 49:449-56. 2013
    ..The aim was to determine prognostic factors for the AYA population...
  25. ncbi request reprint Palifosfamide, a bifunctional alkylator for the treatment of sarcomas
    Susanne Jung
    Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D 69120 Heidelberg, Germany
    IDrugs 13:38-48. 2010
    ....
  26. doi request reprint Pazopanib: a promising new agent in the treatment of soft tissue sarcomas
    Bernd Kasper
    University of Heidelberg, Mannheim University Medical Center, Interdisciplinary Tumor Center Mannheim, Sarcoma Unit, Theodor Kutzer Ufer 1 3, D 68167 Mannheim, Germany
    Future Oncol 7:1373-83. 2011
    ..This article focuses on its emerging role in the treatment of advanced soft tissue sarcomas...
  27. doi request reprint Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways
    Ralf J Rieker
    Institute of Pathology, University Hospital, INF 220 221, 69120, Heidelberg, Germany
    Virchows Arch 456:277-85. 2010
    ..These data indicate that dedifferentiated LS follow separate tumourigenic pathways and that genetic analysis is important to unravel these differences...
  28. ncbi request reprint Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?
    Bernd Kasper
    Department of Internal Medicine V, University of Heidelberg, Hospitalstrasse 3, 69115 Heidelberg, Germany
    Support Care Cancer 12:205-7. 2004
    ..Under preventive therapy with methylene blue, thiamin, and glucose 5% infusions, no encephalopathy occurred...
  29. doi request reprint Dynamic PET with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a 2-tissue compartment model
    Antonia Dimitrakopoulou-Strauss
    Medical PET Group Biological Imaging, Clinical Cooperation Unit Nuclear Medicine, German
    Clin Nucl Med 37:943-8. 2012
    ..A comparison between the regression-based quantitative data (slope and intercept values) with the compartmental data of FDG was performed...
  30. doi request reprint Surgical management and minimally invasive approaches for the treatment of metastatic sarcoma
    Peter Hohenberger
    From the Division of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, University of Heidelberg, Theodor Kutzer Ufer, Mannheim, Germany Interdisciplinary Sarcoma Center, University Hospital Mannheim, Theodor Kutzer Ufer, Mannheim, Germany Interventional Radiology and Thoracic Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
    Am Soc Clin Oncol Educ Book 2013:457-64. 2013
    ..These highly selected and specific procedures should only be performed after decision making in an interdisciplinary sarcoma-board...
  31. ncbi request reprint Atypical manifestations of multiple myeloma: radiological appearance
    Thomas Hess
    Department of Radiology, St Vincenz Hospital, Auf dem Schafsberg, D 65549 Limburg, Germany
    Eur J Radiol 58:280-5. 2006
    ..Extramedullary plasma-cell tumours (plasmocytoma) are found in about 5% of newly diagnosed patients with multiple myelomas. In this paper we present eight patients with atypical forms of multiple myeloma...